New anthraquinone derivatives as inhibitors of the HIV-1 reverse transcriptase-associated ribonuclease H function

Chemotherapy. 2012;58(4):299-307. doi: 10.1159/000343101. Epub 2012 Oct 31.

Abstract

Background: The degradative activity of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), termed ribonuclease H (RNase H), which hydrolyzes the RNA component of the heteroduplex RNA:DNA replication intermediate, is an excellent target for drug discovery. Anthraquinones (AQs) and their derivatives, which are common secondary metabolites occurring in bacteria, fungi, lichens and a large number of families in higher plants, have been reported to have several biological activities including that of inhibiting HIV-1 RT activities in biochemical assays.

Methods: We have assayed new AQ derivatives on HIV-1 RNase H activities in biochemical assays.

Results: Six series of new AQ derivatives with various substituents at positions 1, 2, 3 and 4 of the AQ ring were tested, and new analogs able to inhibit HIV-1 RT-associated RNase H activity in the low micromolar range were found.

Conclusions: Our results demonstrate that AQ derivatives are promising anti-RNase H inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthraquinones / chemistry*
  • Anthraquinones / metabolism
  • HIV-1 / enzymology*
  • Humans
  • Kinetics
  • Protein Binding
  • Recombinant Proteins / antagonists & inhibitors
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / genetics
  • Reverse Transcriptase Inhibitors / chemistry*
  • Reverse Transcriptase Inhibitors / metabolism
  • Ribonuclease H / antagonists & inhibitors*
  • Ribonuclease H / genetics
  • Ribonuclease H / metabolism

Substances

  • Anthraquinones
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors
  • Ribonuclease H